Loading
HC
Heska Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 Jan 2023.
Heska Corp: what insiders have been doing
Heska Corp, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of Heska Corp in twelve months, the latest record being from 14 June 2023.
The full history, which starts in 2016, counts 4 purchases against 4 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
66
Thresholds
n/a
Buy Volume
€752,365
4 ops. · all time
Sell Volume
€84,535
4 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$221.5M
Gross profitUS$95.7M43% margin
Net income-US$17.1M-7.7% margin
Last declaration on 14 June 2023
Declarations66 total
6,881 shares@ US$120.00100.0% of flowCommon StockSEC:0001140361-23-029896:0
21,653 shares@ US$120.0095.1% of flowCommon StockSEC:0001140361-23-029893:0
8,608 shares@ US$120.00100.0% of flowCommon StockSEC:0001140361-23-029899:0
2,004 shares@ US$120.00100.0% of flowCommon StockSEC:0001140361-23-029895:0
4,726 shares@ US$120.00100.0% of flowCommon StockSEC:0001140361-23-029897:0
2,189 shares@ US$120.00100.0% of flowCommon StockSEC:0001140361-23-029898:0
2,553 shares@ US$120.00100.0% of flowCommon StockSEC:0001140361-23-029900:0
15,157 shares0Common StockSEC:0001140361-23-029889:0
33,111 shares0Common StockSEC:0001140361-23-029894:0
16,757 shares0Common StockSEC:0001140361-23-029891:0
211,375 shares0Common StockSEC:0001140361-23-029892:0
44,456 shares0Common StockSEC:0001140361-23-029888:0
38,096 shares0Common StockSEC:0001140361-23-029890:0
906 shares0Common StockSEC:0001140361-23-028343:0
4,057 shares0Common StockSEC:0001237648-23-000015:0
4,057 shares0Common StockSEC:0001237648-23-000014:0
3,949 shares0Common StockSEC:0001237648-23-000012:0
4,327 shares0Common StockSEC:0001237648-23-000013:0
4,057 shares0Common StockSEC:0001237648-23-000016:0
5,000 shares0Common StockSEC:0001237648-23-000004:0
5,653 shares@ US$58.2237.6% of flowCommon StockSEC:0001237648-23-000002:0
Canonical exit: 6 Apr 2023 (T+90)
2,299 shares@ US$59.6515.5% of flowCommon StockSEC:0001237648-22-000050:0
Canonical exit: 22 Mar 2023 (T+90)
750 shares0Common StockSEC:0001237648-22-000048:0
750 shares0Common StockSEC:0001237648-22-000046:0
10,000 shares@ US$8.5531.7% of flowCommon StockSEC:0001237648-22-000044:0
25 of 66 declarations
About Heska Corp
Heska Corp. (ticker HSKA) was a United States animal-health company best known for veterinary diagnostics and specialty products for companion animals. Historically listed on the NASDAQ market in the United States, Heska was acquired by Mars, Inc., with the transaction announced in April 2023 and completed on June 13, 2023. As a result, Heska became part of Mars Petcare’s Science & Diagnostics division, which materially expanded its scale and global reach in veterinary diagnostics. The company was founded in 1988 and built its franchise around a focused but strategically attractive niche: providing veterinarians with tools for clinical testing, monitoring, and workflow support for dogs and cats. ([mars.com](https://www.mars.com/news-and-stories/press-releases-statements/mars-to-acquire-heska-global-provider-advanced-veterinary-solutions?utm_source=openai))
Heska’s business model was centered on three core lines: point-of-care diagnostic instruments, recurring consumables tied to those instruments, and software/informatics solutions for veterinary practices. Its portfolio included in-clinic laboratory analyzers, digital imaging products, rapid diagnostic tests, data services, and allergy/immunotherapy offerings. The company also broadened its software capabilities in Europe through the 2022 acquisition of VetZ GmbH, a veterinary practice information management software provider. That combination of hardware, consumables, and software gave Heska a more integrated profile than a pure-play device manufacturer and supported recurring revenue opportunities through consumable usage and service relationships. ([nasdaq.com](https://www.nasdaq.com/press-release/heska-to-host-virtual-2022-investor-day-on-may-17-2022-2022-04-29?utm_source=openai))
Read moreShow less
Before the Mars transaction, Heska operated as a specialized player in animal health with North American and international exposure. Its headquarters were in Loveland, Colorado, United States. Competitive positioning was built around a “full-stack” offering for veterinary clinics: diagnostics, imaging, informatics, and specialty products, with a strong emphasis on companion-animal care. In structural terms, that positioned Heska in a favorable end-market, as veterinary clinics have increasingly invested in more advanced in-house testing and digital workflows, while pet healthcare spending has continued to rise over time. ([sec.place](https://sec.place/companies/heska-corp-1038133?utm_source=openai))
The key recent corporate event is the Mars acquisition. Mars and Heska announced a definitive agreement on April 3, 2023, under which Mars agreed to acquire Heska for $120.00 per share. The deal closed on June 13, 2023, and Mars said the combination would broaden access to diagnostics and technology while accelerating R&D and innovation. For investors, the practical takeaway is that HSKA is no longer a conventional standalone U.S.-listed equity on NASDAQ, but its legacy remains that of a U.S.-based veterinary diagnostics specialist with a strong technology-led product mix and a meaningful role in the global companion-animal health market. ([mars.com](https://www.mars.com/news-and-stories/press-releases-statements/mars-to-acquire-heska-global-provider-advanced-veterinary-solutions?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
